Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453111 | 1.00 | IP6K1 (0.34) | IP6K1HSD11B1IP6K3ROCK2ADORA3 | |
| SCHEMBL3453109 | 1.00 | IP6K1 (0.34) | IP6K1HSD11B1IP6K3ROCK2ADORA3 | |
| SCHEMBL3453285 | 0.93 | PIK3CA (0.36) | ROCK2 | |
| SCHEMBL3453284 | 0.93 | PIK3CA (0.36) | ROCK2 | |
| SCHEMBL3453287 | 0.93 | PIK3CA (0.36) | ROCK2 | |
| SCHEMBL3452841 | 0.89 | ROCK2 (0.34) | HSD11B1ROCK2 | |
| SCHEMBL3453865 | 0.89 | ADRA1A (0.32) | HSD11B1ROCK2 | |
| SCHEMBL3453539 | 0.88 | HSD11B1 (0.38) | HSD11B1ROCK2 | |
| SCHEMBL3454276 | 0.88 | HTR2B (0.34) | — | |
| SCHEMBL3454274 | 0.88 | HTR2B (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029576-B1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-06-19 | — | — | EP | claimed |
| US-7820659-B2 | Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-10-26 | — | — | US | claimed |
| US-20090088428-A1 | CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | claimed |
| EP-2029576-B1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088428-A1 | CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | IP6K1 1766/4885HSD11B1 1/4885IP6K3 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.